Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

FDA rejects Immunomedics breast cancer drug, extending long regulatory drought

  • Adam Feuerstein

By Adam Feuerstein Jan. 17, 2019

Reprints
FDA
Andrew Harnik/AP

The 37-year drug development drought lives on.

Immunomedics (IMMU), the biotech founded in 1982, was informed by the Food and Drug Administration on Thursday night that its lead drug, an antibody drug conjugate to treat women with an aggressive form of breast cancer, could not be approved at this time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Marburg fever outbreak in Equatorial Guinea widens, WHO reports
Marburg fever outbreak in Equatorial Guinea widens, WHO reports
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
Researchers devise new strategies to overcome a key CRISPR…
Researchers devise new strategies to overcome a key CRISPR flaw
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
The lesson biotech absolutely should not take from Silicon…
The lesson biotech absolutely should not take from Silicon Valley Bank’s failure
Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
Senators interrogate health secretary Becerra on Alzheimer’s drug coverage

Comments are closed.

Recommended Stories